HROW Harrow, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 10, 2026HROW Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
HROW Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
| Date ex-dividende | Division | Type |
|---|---|---|
| 8 février 2013 | 1-for-5 | Inverse |
| 24 février 2012 | 1-for-8 | Inverse |
À propos de Harrow, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | HROW | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -31.4moyenne 5 ans ≈-115.6 | ≈-115.6 | · | · | |
| P/S (TTM) | 4.1moyenne 5 ans ≈4.8 | ≈4.8 | · | · | |
| P/B (MRQ) | 75.2moyenne 5 ans ≈18.8 | ≈18.8 | 3.2 | Surévalué | |
| Cours / FCF (TTM) | 227.8moyenne 5 ans ≈-53.3 | ≈-53.3 | · | · | |
| Cours / Flux de trésorerie (TTM) | 182.7moyenne 5 ans ≈79.0 | ≈79.0 | · | · | |
| Cours / Actif net tangible (MRQ) | -7.1 | · | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | HROW | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge Brute (TTM) | 73.3%moyenne 5 ans ≈73.2% | ≈73.2% | · | · | |
| Marge d'exploitation (TTM) | -1.00%moyenne 5 ans ≈4.1% | ≈4.1% | 2.2% | Faible | |
| EBITDA Margin (Marge EBITDA) | 11.7%moyenne 5 ans ≈5.2% | ≈5.2% | 2.4% | Faible | |
| Marge avant impôts (TTM) | -12.1%moyenne 5 ans ≈-13.6% | ≈-13.6% | 9.0% | Faible | |
| Marge nette (TTM) | -13.5%moyenne 5 ans ≈-14.0% | ≈-14.0% | 4.5% | Faible | |
| ROA (TTM) | -9.8%moyenne 5 ans ≈-10.2% | ≈-10.2% | -0.40% | Inférieur à la moyenne | |
| ROE (TTM) | -114.8%moyenne 5 ans ≈-49.8% | ≈-49.8% | -3.7% | Inférieur à la moyenne | |
| ROIC | 218.6%moyenne 5 ans ≈50.7% | ≈50.7% | 7.9% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | HROW | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Ratio de liquidité (MRQ) | 2.2moyenne 5 ans ≈3.9 | ≈3.9 | 4.0 | Faible liquidité | |
| Quick Ratio (Ratio de liquidité réduite) | 1.9moyenne 5 ans ≈2.3 | ≈2.3 | 2.6 | Inférieur à la moyenne |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | HROW | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 36.4%moyenne 5 ans ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 45.4%moyenne 5 ans ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 41.0% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | HROW | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.7moyenne 5 ans ≈0.7 | ≈0.7 | 0.7 | Premier rang | |
| Inventory Turnover (Rotation des stocks) | 5.6moyenne 5 ans ≈4.8 | ≈4.8 | 2.1 | Premier rang | |
| Receivables Turnover (Rotation des créances) | 2.4moyenne 5 ans ≈9.6 | ≈9.6 | 5.1 | Faible | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$730.0K | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 11, 2026 | $-0.46 | $-0.18 | -150.5% |
| 31 mars 2026 | Mai 7, 2026 | $-0.74 | $-0.41 | -80.7% |
| 31 décembre 2025 | $0.17 | $0.38 | -54.8% | |
| 30 septembre 2025 | $0.22 | $0.27 | -18.1% | |
| 30 juin 2025 | $0.13 | $0.01 | — | |
| 31 mars 2025 | $-0.50 | $-0.05 | -970.7% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.41 | $1.96 | $2.01 | $0.92 | $0.42 | $1.06 | $1.09 | $1.02 | $0.13 | $0.35 | $-0.14 | $0.88 | |
| Revenue / Share | $7.41 | $5.60 | $3.99 | · | · | $1.89 | $1.93 | $1.74 | · | · | · | · | |
| Cash Flow / Share | $1.19 | $-0.62 | $0.12 | · | · | $-0.04 | $0.04 | $0.03 | · | · | · | · | |
| Cash / Share | $1.96 | $1.33 | $2.11 | · | $1.57 | $0.16 | · | · | $0.19 | $0.48 | $0.28 | $0.89 | |
| EPS (TTM) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | · | 37,145,440 | 36,790,306 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | · | 38,875,005 | 38,853,855 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $0.77 | · | $1.27 | $1.35 | $1.58 | · | $1.63 | $1.65 | $1.71 | · | $2.16 | $0.74 | $0.73 | · | $0.04 | |
| Revenue / Share | $1.89 | $1.19 | · | $1.84 | $1.64 | $1.34 | · | $1.38 | $1.37 | $0.98 | · | $1.00 | $1.10 | $0.86 | · | · | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $0.55 | · | · | · | $-0.13 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $2.24 | $2.54 | · | $2.01 | $1.44 | $1.87 | · | $2.04 | $2.00 | $1.94 | · | $1.87 | · | · | · | $1.66 | |
| EPS (TTM) | $-0.97 | $-0.38 | · | $-0.15 | $-0.30 | $-0.61 | · | $-0.94 | $-0.95 | $-0.91 | · | $-0.44 | $-0.55 | $-0.64 | · | · |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $276M | $269M | · | $250M | $228M | $213M | · | $169M | $154M | $139M | · | $114M | $103M | $93M | · | $88M | |
| Net Income TTM | $-37M | $-15M | · | $-5M | $-10M | $-22M | · | $-33M | $-34M | $-31M | · | $-14M | $-16M | $-18M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -43.8 | -92.8 | · | -321.2 | -101.8 | -43.6 | · | -47.8 | -22.0 | -14.5 | · | -32.7 | -34.6 | -33.1 | · | · | |
| P/S | 5.8 | 4.9 | · | 7.1 | 4.9 | 4.5 | · | 9.5 | 4.8 | 3.4 | · | 4.4 | 5.6 | 6.9 | · | 3.7 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| EV / Revenue | · | · | · | 7.8 | 5.5 | 4.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.3% | -1.1% | · | -0.31% | -0.98% | -2.3% | · | -2.1% | -4.5% | -6.9% | · | -3.1% | -2.9% | -3.0% | · | · |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $272M | $200M | $130M | $89M | $72M |
| Marge Brute % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Marge d'exploitation % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Résultat net | $-5M | $-17M | $-24M | $-14M | $-18M |
| BPA dilué | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio de liquidité | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Ratio de liquidité réduite | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $43M | $-24M | $2M | $-892.0K | $3M |
Détenteurs institutionnels (13F) 243 déclarants · $1.1B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 41 (-6 vs T. préc.) | 34 (+4 vs T. préc.) | 80 (+11 vs T. préc.) | 69 (-9 vs T. préc.) | -305K |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $116 372 768 | 2 740 117 | 10,90% | Actions |
| Opaleye Management Inc. | $101 928 000 | 2 400 000 | 9,55% | Actions |
| VANGUARD GROUP INC | $94 162 467 | 1 921 683 | 8,82% | Actions |
| Private Capital Management, LLC | $67 899 762 | 1 598 770 | 6,36% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $60 188 994 | 1 417 212 | 5,64% | Actions |
| Deep Track Capital, LP | $41 153 430 | 969 000 | 3,86% | Actions |
| STATE STREET CORP | $39 917 043 | 939 888 | 3,74% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $38 466 487 | 905 560 | 3,60% | Actions |
| BAMCO INC /NY/ | $34 373 094 | 809 350 | 3,22% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31 550 963 | 742 900 | 2,96% | Option d'achat |
| DIMENSIONAL FUND ADVISORS LP | $28 325 286 | 667 036 | 2,65% | Actions |
| Divisadero Street Capital Management, LP | $18 650 913 | 439 155 | 1,75% | Actions |
| CITADEL ADVISORS LLC | $16 622 758 | 391 400 | 1,56% | Option d'achat |
| RICE HALL JAMES & ASSOCIATES, LLC | $16 459 036 | 387 545 | 1,54% | Actions |
| MARSHALL WACE, LLP | $15 689 905 | 369 435 | 1,47% | Actions |
| CITADEL ADVISORS LLC | $15 283 849 | 359 874 | 1,43% | Actions |
| NORTHERN TRUST CORP | $13 726 559 | 323 206 | 1,29% | Actions |
| Schonfeld Strategic Advisors LLC | $13 574 473 | 319 625 | 1,27% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13 531 367 | 318 610 | 1,27% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11 623 869 | 273 696 | 1,09% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $9 998 202 | 235 418 | 0,94% | Actions |
| CITADEL ADVISORS LLC | $9 895 510 | 233 000 | 0,93% | Option de vente |
| Westside Investment Management, Inc. | $9 515 477 | 224 051 | 0,89% | Actions |
| FirstWave Capital Management LLC | $9 002 833 | 211 981 | 0,84% | Actions |
| Blackhawk Capital Partners, LLC | $8 631 645 | 203 241 | 0,81% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8 074 227 | 190 116 | 0,76% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7 827 221 | 184 300 | 0,73% | Option de vente |
| JANE STREET GROUP, LLC | $7 772 010 | 183 000 | 0,73% | Option d'achat |
| STIFEL FINANCIAL CORP | $7 682 532 | 180 893 | 0,72% | Actions |
| GOLDMAN SACHS GROUP INC | $6 573 380 | 154 777 | 0,62% | Actions |
| ROYCE & ASSOCIATES LP | $6 565 310 | 154 587 | 0,62% | Actions |
| Crawford Fund Management, LLC | $6 035 836 | 142 120 | 0,57% | Actions |
| Ikarian Capital, LLC | $5 766 364 | 135 775 | 0,54% | Actions |
| Advantage Alpha Capital Partners LP | $5 374 624 | 111 553 | 0,50% | Actions |
| MORGAN STANLEY | $5 105 094 | 120 204 | 0,48% | Actions |
| Diametric Capital, LP | $4 965 082 | 116 908 | 0,47% | Actions |
| WOODMONT INVESTMENT COUNSEL LLC | $4 748 571 | 111 810 | 0,44% | Actions |
| BANK OF AMERICA CORP /DE/ | $4 565 398 | 107 497 | 0,43% | Actions |
| FIRST TRUST ADVISORS LP | $4 260 378 | 100 315 | 0,40% | Actions |
| STATE OF WISCONSIN INVESTMENT BOARD | $4 146 219 | 97 627 | 0,39% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $3 934 590 | 92 644 | 0,37% | Actions |
| 12th Street Asset Management Company, LLC | $3 882 140 | 91 409 | 0,36% | Actions |
| Lumbard & Kellner, LLC | $3 835 975 | 90 322 | 0,36% | Actions |
| Steward Partners Investment Advisory, LLC | $3 832 960 | 90 251 | 0,36% | Actions |
| Bank of New York Mellon Corp | $3 625 366 | 85 363 | 0,34% | Actions |
| MILLENNIUM MANAGEMENT LLC | $3 575 210 | 84 182 | 0,33% | Actions |
| EQUITABLE TRUST CO | $3 371 184 | 79 378 | 0,32% | Actions |
| Squarepoint Ops LLC | $3 126 726 | 73 622 | 0,29% | Actions |
| DEUTSCHE BANK AG\ | $3 009 509 | 70 862 | 0,28% | Actions |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 004 668 | 70 748 | 0,28% | Actions |
Activistes et détenteurs de 5%+ 5 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Mark L. Baum ×3 dépôts | 7 avril 2025 | 10,69% | Amendement | · | SEC |
| 27 avril 2021 | · | Dépôt initial | · | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 dépôts | 30 août 2016 | · | Dépôt initial | Investissement passif | SEC |
| Dr. Robert J. Kammer ×2 dépôts | 16 août 2013 | · | Dépôt initial | · | SEC |
| DermaStar International, LLC ×7 dépôts | 10 août 2012 | · | Dépôt initial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 32 initiés · 10 dirigeants · 17 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER | 14 mai 2026 P | 2 996 130 | 1 | 0 | $302 000 |
| John P. Saharek | CEO & President, ImprimisRx | 3 avril 2025 M | 467 388 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 juin 2009 A | 1 954 125 | 0 | 0 | $0 |
| Andrew Boll | PRESIDENT AND CFO | 14 mai 2026 P | 814 679 | 1 | 0 | $104 650 |
| Clayton D Edwards | Chief Operating Officer | 13 avril 2017 A | · | 0 | 0 | $0 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 14 août 2026 M | 0 | 0 | 1 | $-450 000 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 janvier 2026 A | · | 0 | 0 | $0 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 1 septembre 2025 A | · | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1 avril 2013 A | · | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 février 2010 A | · | 0 | 0 | $0 |
| Perry J. Sternberg | Administrateur | 18 juin 2026 A | · | 0 | 0 | $0 |
| Adrienne L Graves | Administrateur | 18 juin 2026 A | 1 000 | 1 | 0 | $31 070 |
| Lauren P Silvernail | Administrateur | 18 juin 2026 A | 1 000 | 1 | 0 | $31 000 |
| Martin A. Makary | Administrateur | 14 juin 2024 A | 45 000 | 0 | 0 | $0 |
| Teresa Sparks | Administrateur | 21 juin 2023 A | · | 0 | 0 | $0 |
| Lawrence R. Van Horn | Administrateur | 21 juin 2023 A | 1 860 | 0 | 0 | $0 |
| Richard L Lindstrom MD | Administrateur | 30 septembre 2022 S | 26 100 | 0 | 0 | $0 |
| Robert J Kammer | Administrateur | 25 juin 2021 A | 797 327 | 0 | 0 | $0 |
| Anthony Principi | Administrateur | 28 septembre 2020 M | 93 798 | 0 | 0 | $0 |
| Stephen G Austin | Administrateur | 16 mars 2020 M | 91 987 | 0 | 0 | $0 |
| William H. Nelson | Administrateur | 10 juin 2016 A | 12 904 | 0 | 0 | $0 |
| August Shelby Bassani | Administrateur | 4 septembre 2014 A | 13 488 | 0 | 0 | $0 |
| Peter C Kenny | Administrateur | 2 octobre 2013 A | 8 947 | 0 | 0 | $0 |
| Paul Finnegan | Administrateur | 27 juin 2013 A | 6 865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Administrateur | 27 juin 2013 A | 45 927 | 0 | 0 | $0 |
| Opaleye Management Inc. | Détenteur de 10% | 4 mars 2026 S | 59 428 | 0 | 6 | $-9 183 890 |
| Donald Paul Miloni | Détenteur de 10% | 19 mai 2015 S | 468 576 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Détenteur de 10% | 12 juillet 2012 J | 0 | 0 | 0 | $0 |
| John N Bonfiglio | · | 20 octobre 2010 A | 50 000 | 0 | 0 | $0 |
| John T Lomoro | · | 19 juin 2009 A | · | 0 | 0 | $0 |
| Lynn C Swann | · | 21 novembre 2008 A | 25 000 | 0 | 0 | $0 |
| Anthony S Thornley | · | 21 novembre 2008 A | 60 900 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 32 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,23% | 6 543 NS | 31 juillet 2026 | N-PORT |
| IWC · iShares Trust | 0,28% | 110 031 SH | 11 septembre 2026 | Quotidien |
| IHE · iShares Trust | 0,28% | 122 556 SH | 11 septembre 2026 | Quotidien |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,25% | 82 646 NS | 31 juillet 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 41 081 NS | 31 juillet 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34 722 SH | 19 août 2026 | Quotidien |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 50 393 NS | 31 juillet 2026 | N-PORT |
| IWO · iShares Trust | 0,08% | 302 749 SH | 11 septembre 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 2 662 SH | 1 octobre 2026 | Quotidien |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 7 488 NS | 31 juillet 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 7 406 NS | 31 juillet 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 15 475 NS | 31 juillet 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186 298 SH | 19 août 2026 | Quotidien |
| IWM · iShares Trust | 0,04% | 826 648 SH | 11 septembre 2026 | Quotidien |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2 979 SH | 1 octobre 2026 | Quotidien |
| ISCG · iShares Trust | 0,03% | 8 739 SH | 11 septembre 2026 | Quotidien |
| DFAS · Dimensional ETF Trust | 0,03% | 125 599 NS | 31 juillet 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383 679 SH | 19 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,02% | 94 953 SH | 19 août 2026 | Quotidien |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 15 109 NS | 31 juillet 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2 287 SH | 11 septembre 2026 | Quotidien |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 31 juillet 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 61 585 NS | 31 juillet 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10 408 NS | 31 juillet 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 2 739 NS | 31 juillet 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11 363 NS | 31 juillet 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45 401 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,00% | 7 042 SH | 4 septembre 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 001 445 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 637 SH | 19 août 2026 | Quotidien |
| ISCB · iShares Trust | · | 1 222 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 34 093 SH | 11 septembre 2026 | Quotidien |
HROW Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
Objectif de cours à 12 mois
9 analystes · 2026-09-29Objectif moyen $65.00 +113,3%
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| SPTX | · | · | · | · | · | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.